D e s i g n
Cohort study with 3.7 to 8.8 years of follow-up.
S e t t i n g
A university hospital in Göteborg, Sweden. P a t i e n t s 738 patients with DVT confirmed by phlebography or color duplex ultrasonography who had been discharged from the hospital and survived to 1 month. 591 patients (mean age 66 y, 53% women) had a first DVT, and 147 patients had previous VTEs (108 patients with a previous DVT, 19 with a previous PE, and 20 with both DVT and PE). Follow-up for mortality was > 99%.
A s s e s s m e n t o f p r o g n o s t i c f a c t o r s
Data on prognostic factors were collected and used in multivariate analyses: age, sex, duration of oral anticoagulant therapy, location of DVT (arm or leg), level of DVT in leg (distal or proximal), initial antithrombotic treatment, history of VTE, surgery within the past 3 months, immobilization within 1 week of index DVT, and cancer. 
C o n c l u s i o n s
The recurrence rate of venous thromboembolism was high. The risk for recurrence was increased if the index event was a proximal deep venous thrombosis, if the patient had a history of venous thromboembolism or cancer but not recent surgery, or if the duration of the initial anticoagulant therapy period had been short. 
Sources of funding: Swedish Medical Research

C o m m e n t a r y
Hansson and colleagues have shown that rates of recurrent VTE remain high despite the standard clinical practice of 3 months of prophylactic oral anticoagulation. Kearon and colleagues (1) eloquently showed that after an initial episode of idiopathic VTE the rate of recurrence was 27.4%/patient-year with placebo and 1.3%/patientyear with continued warfarin. Schulman and colleagues (2) found that prophylactic oral anticoagulation after initial VTE for 6 months rather than 6 weeks reduced recurrence rates. Furthermore, long-term prophylaxis after a second VTE resulted in lower recurrence rates than did 6 months of prophylaxis, although with more major bleeding (3). These studies provide compelling evidence that VTE should be viewed as a "chronic polygenic disorder" (4) with acute exacerbations and that extended prophylactic anticoagulation in patients with idiopathic VTE and VTE associated with persistent risk factors for thrombosis needs to be strongly considered. Hansson and colleagues did not present data on the presence of factor V Leiden, 1 of the most common inherited hypercoagulable states associated with recurrent VTE (5) . It is unclear whether long-term prophylaxis in patients with factor V Leiden who have an initial VTE is warranted, considering that the risk for anticoagulant-related bleeding is directly associated with the duration of therapy (6) . The results of an ongoing trial to assess the efficacy of extended low-dose warfarin in the secondary prevention of VTE among patients with and without factor V Leiden will, I hope, provide much-needed answers (7) . 
